



Endostart secures CE marking for Endorail® - extending application from colonoscopy to enteroscopy, making complex procedures more accessible

Magnetic balloon technology enhances control of endoscope for small and large bowel procedures

Certaldo, Italy, October 11, 2024 – Endostart, a pioneering medical device company specializing in gastrointestinal endoscopy solutions, today announces that it has obtained CE marking for the expanded use of its flagship product, Endorail®. This milestone extends Endorail's application to enteroscopy, making this challenging procedure more accessible and widely available, significantly advancing gastrointestinal endoscopy and improving patient care.

Already available in Italy, the UK and France, Endorail revolutionizes endoscopic procedures by increasing efficiency and safety. With this new CE marking, Endorail now offers a solution for enteroscopy, which is critical for diagnosing and treating small bowel conditions, such as cancer, bleeding and chronic inflammatory diseases. However, it is often lengthy and difficult to perform.

“We are thrilled to obtain the CE mark for small bowel procedures. This milestone has the potential to be a game-changer in managing small bowel diseases. It highlights our commitment to innovation and our dedication to developing tools that enhance patient care,” said Dr. Alessandro Tozzi, co-founder and CEO at Endostart.

Endostart will showcase an updated version of Endorail at the [UEG Week conference](#) in Vienna, Austria, from October 12–15, highlighting new features for both colonoscopy and enteroscopy.

[Endorail](#) leverages a magnetic balloon system, providing enhanced control of the endoscope in both the small and large bowel. The system uses a magnetically anchored balloon to stabilize and guide the endoscope, reducing looping and improving manoeuvrability. This innovation simplifies the colonoscopy process and now improves enteroscopy by aiding both balloon-assisted and push enteroscopy procedures. With its user-friendly design, Endorail is aimed at empowering physicians to improve procedural performance, ensuring more effective and efficient outcomes while reducing the healthcare costs associated with prolonged or incomplete procedures.

“Currently, therapeutic enteroscopy is only available at a limited number of hospitals and few endoscopists are trained to perform these complex procedures. The goal for Endostart is to make enteroscopy more accessible on a large scale, including community hospitals,” said Christopher Rowland, chairman of the board at Endostart.

“Magnetic balloon-assisted enteroscopy has the potential to transform procedures, not only for small bowel conditions like bleeding or polyps, but also for challenging treatments such as Endoscopic Retrograde CholangioPancreatography (ERCP) in altered anatomy,” added Prof. Alessandro Repici, director of the Digestive Endoscopy Unit at [Humanitas Research Hospital](#), Milan, Italy.

Since its founding in 2018, Endostart has been committed to developing cutting-edge medical devices to meet the evolving needs of healthcare professionals and patients. The [endoscopic devices market](#)

was valued at approximately \$52.75 billion in 2023 and is expected to grow at a CAGR of 7.1% from 2024 to 2033. Endostart's magnetic balloon technology positions the company as a leader in advancing endoscopic procedures and setting new standards in gastrointestinal healthcare.

Supported by a team of experienced industry professionals and guided by an international board of directors, Endostart is poised for continued growth in the global medical device market. The company's platform of innovative tools addresses both diagnostic and therapeutic needs, further expanding its influence in the gastrointestinal endoscopy field.

About Endostart

Endostart is a pioneering medical device company specializing in gastrointestinal endoscopy solutions. Founded in 2018, the company has developed a next-generation magnetic balloon technology solution aimed at enhancing endoscopic procedures and enabling endoscopists to perform tasks with greater efficiency and precision. Endostart is supported by private investors, led by a highly professional team and an international board of directors.

www.endostart.com

For more information, please contact:

- Email: info@endostart.com
- Phone: +39 0571 843033
- Address: Via delle Regioni, 265 - 50052 Certaldo (FI), Italy

Media and analysts contact

Andrew Lloyd & Associates

Carol Leslie / Juliette Schmitt

carol@ala.associates / juliette@ala.associates

UK: +44 1273 952 481

US: +1 203 724 5950
